Related Experiment Videos
Soluble CD8 in patients with rheumatic diseases
J A Symons1, N C Wood, F S di Giovine
1University of Edinburgh Department of Medicine, Northern General Hospital, Edinburgh, UK.
Clinical and Experimental Immunology
|June 1, 1990
Summary
Soluble CD8 (sCD8) levels are elevated in rheumatoid arthritis (RA) patients, correlating with disease activity. Monitoring sCD8 may offer insights into RA
Area of Science:
- Immunology
- Rheumatology
- Biochemistry
Background:
- Rheumatic diseases, particularly rheumatoid arthritis (RA), involve complex immune dysregulation.
- Soluble immune markers can serve as indicators of disease activity and progression.
Purpose of the Study:
- To investigate the levels and potential role of soluble CD8 (sCD8) in rheumatic diseases, with a focus on RA.
- To explore the relationship between sCD8, disease activity, and immune cell function in RA patients.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was employed to quantify sCD8 in serum and synovial fluid (SF).
- Mononuclear cells from SF and peripheral blood were analyzed for sCD8 production.
- The impact of tumor necrosis factor alpha (TNF-α) on sCD8 release was assessed.
Main Results:
- Elevated serum and SF sCD8 levels were observed in RA patients compared to osteoarthritis patients and healthy controls.
- Serial sCD8 measurements in RA patients showed dynamic changes preceding clinical improvement and disease flares.
- RA synovial fluid mononuclear cells (SFMNC) spontaneously produced high levels of sCD8, potentiated by TNF-α.
Conclusions:
- Soluble CD8 is a potential biomarker for rheumatoid arthritis activity and immune response.
- CD8+ T cells likely play a significant immunoregulatory role in the pathogenesis of RA.